Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01942135
First received: September 10, 2013
Last updated: September 9, 2014
Last verified: September 2014
  Purpose

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant (Faslodex®) over fulvestrant alone in prolonging PFS in women with HR+, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy. The safety between the two treatment arms will also be compared. During study treatment, pre- and perimenopausal women must be receiving therapy with the LHRH agonist goserelin (Zoladex® or generic).


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Palbociclib
Drug: Fulvestrant
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex®) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Progression-Free Survival [ Time Frame: Baseline up to approximately 10 months ] [ Designated as safety issue: No ]
    Time from randomization to the first documentation of objective tumor progression or to death due to any cause.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Baseline until death (up to approximately 28 months) ] [ Designated as safety issue: No ]
    Time from randomization to date of death due to any cause.

  • Objective Response [ Time Frame: Baseline until approximately 10 months ] [ Designated as safety issue: No ]
    Complete or partial response recorded from randomization until disease progression or death due to any cause.

  • Duration of Response [ Time Frame: Baseline up to approximately 10 months ] [ Designated as safety issue: No ]
    Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause.

  • Clinical Benefit Response (CBR) [ Time Frame: Baseline up to approximately 10 months ] [ Designated as safety issue: No ]
    CBR is defined as complete response or partial response or stable disease equal to or greater than 24 weeks according to RECIST version 1.1 recorded in the time period between randomization and disease progression or death of any cause.

  • 1 Year Probability of Participant Survival [ Time Frame: From baseline through 1 year ] [ Designated as safety issue: No ]
    Probability of survival one year after randomization.

  • 2 Year Probability of Participant Survival [ Time Frame: From baseline through 2 years ] [ Designated as safety issue: No ]
    Probability of survival 2 years after randomization

  • 3 Year Probability of Participant Survival [ Time Frame: From baseline through 3 years ] [ Designated as safety issue: Yes ]
    Probability of survival 3 years after randomization.

  • Minimum Observed Plasma Trough Concentration (Cmin) [ Time Frame: Cycles 1 and 2 ] [ Designated as safety issue: No ]
    Cmin for palbociclib, fulvestrant and goserelin (if applicable)

  • Alterations in genes, proteins, and ribonucleic acids relevant to the cell cycle, drug targets, tumor sensitivity and/or resistance [ Time Frame: From baseline until approximately 10 months ] [ Designated as safety issue: No ]
    Biomarkers from tissue including genes, proteins, and RNA expression

  • Euro Quality of Life (EQ-5D)- Health State Profile Utility Score [ Time Frame: From baseline through approximately month 10 ] [ Designated as safety issue: No ]
    EQ 5D (version 3L) is a 6 item instrument designed to assess health status in terms of a single index value or utility score.

  • European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) [ Time Frame: From baseline through approximately month 10 ] [ Designated as safety issue: No ]
    The EORTC QLQ C30 is a 30 item questionnaire composed of functional subscales; symptom scales; and other cancer related symptoms.

  • European Organization for Research and Treatment of Cancer breast cancer module (EORTC QLQ BR23) [ Time Frame: From baseline through approximately month 10 ] [ Designated as safety issue: No ]
    EORTC QLQ BR23 is a 23 item breast cancer specific companion module to the EORTC QLQ C30.

  • Time to Deterioration (TTD) [ Time Frame: From baseline through approximately month 10 ] [ Designated as safety issue: No ]
    Time from randomization to the first documentation of objective tumor progression, death due to any cause, and/or reduction in quality of life

  • Minimally Important Difference Cut-Off [ Time Frame: From baseline through approximately month 10 ] [ Designated as safety issue: No ]
    Number of time points where the minimally importance difference in QoL is achieved


Estimated Enrollment: 417
Study Start Date: September 2013
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
Drug: Palbociclib
Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
Drug: Fulvestrant
Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
Active Comparator: Arm B
Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
Drug: Placebo
Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
Drug: Fulvestrant
Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy
  • Confirmed diagnosis of HR+/HER2- breast cancer
  • Any menopausal status
  • Progressed within 12 months from prior adjuvant or progressed within 1 month from prior advanced/metastatic endocrine breast cancer therapy
  • On an LHRH agonist for at least 28 days, if pre-/peri-menopausal, and willing to switch to goserelin (Zoladex ®) at time of randomization.
  • Measurable disease defined by RECIST version 1.1, or bone-only disease
  • Eastern Cooperative Oncology Group (ECOG) PS 0-1
  • Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures
  • Patient must agree to provide tumor tissue from metastatic tissue at baseline

Exclusion Criteria:

  • Prior treatment with any CDK inhibitor, fulvestrant, everolimus, or agent that inhibits the PI3K-mTOR pathway
  • Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases
  • Major surgery or any anti-cancer therapy within 2 weeks of randomization
  • Prior stem cell or bone marrow transplantation
  • Use of potent CYP3A4 inhibitors or inducers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01942135

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35249
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
Pfizer Investigational Site
Daphne, Alabama, United States, 36526
Pfizer Investigational Site
Mobile, Alabama, United States, 36607
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
United States, Arizona
Pfizer Investigational Site
Avondale, Arizona, United States, 85323
Pfizer Investigational Site
Chandler, Arizona, United States, 85224
Pfizer Investigational Site
Flagstaff, Arizona, United States, 86002
Pfizer Investigational Site
Gilbert, Arizona, United States, 85297
Pfizer Investigational Site
Glendale, Arizona, United States, 85304
Pfizer Investigational Site
Glendale, Arizona, United States, 85306
Pfizer Investigational Site
Goodyear, Arizona, United States, 85338
Pfizer Investigational Site
Mesa, Arizona, United States, 85202
Pfizer Investigational Site
Mesa, Arizona, United States, 85206
Pfizer Investigational Site
Phoenix, Arizona, United States, 85028
Pfizer Investigational Site
Prescott Valley, Arizona, United States, 86314
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85251
Pfizer Investigational Site
Sedona, Arizona, United States, 86336
Pfizer Investigational Site
Surprise, Arizona, United States, 85374
Pfizer Investigational Site
Tucson, Arizona, United States, 85719
Pfizer Investigational Site
Tucson, Arizona, United States, 85724
United States, California
Pfizer Investigational Site
Alhambra, California, United States, 91801
Pfizer Investigational Site
Bakersfield, California, United States, 93309
Pfizer Investigational Site
Duarte, California, United States, 91010
Pfizer Investigational Site
Fullerton, California, United States, 92835
Pfizer Investigational Site
Glendale, California, United States, 91204
Pfizer Investigational Site
Irvine, California, United States, 92604
Pfizer Investigational Site
La Jolla, California, United States, 92037-0845
Pfizer Investigational Site
La Jolla, California, United States, 92093
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Long Beach, California, United States, 90806
Pfizer Investigational Site
Los Angeles, California, United States, 90033
Pfizer Investigational Site
Los Angeles, California, United States, 90095-7349
Pfizer Investigational Site
Los Angeles, California, United States, 90045
Pfizer Investigational Site
Los Angeles, California, United States, 90095
Pfizer Investigational Site
Oceanside, California, United States, 92056
Pfizer Investigational Site
Orange, California, United States, 92868
Pfizer Investigational Site
Pasadena, California, United States, 91105
Pfizer Investigational Site
Porter Ranch, California, United States, 91326
Pfizer Investigational Site
Redondo Beach,, California, United States, 90281
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Francisco, California, United States, 94115
Pfizer Investigational Site
San Luis Obispo, California, United States, 93401
Pfizer Investigational Site
Santa Ana, California, United States, 92705
Pfizer Investigational Site
Santa Maria, California, United States, 93454
Pfizer Investigational Site
Santa Monica, California, United States, 90404
Pfizer Investigational Site
South Pasadena, California, United States, 91030
Pfizer Investigational Site
Valencia, California, United States, 91105
Pfizer Investigational Site
West Hills, California, United States, 91307
Pfizer Investigational Site
Westlake Village, California, United States, 91361
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
United States, Florida
Pfizer Investigational Site
Deerfield Beach, Florida, United States, 33442
Pfizer Investigational Site
Fort Lauderdale, Florida, United States, 33308
Pfizer Investigational Site
Gainesville, Florida, United States, 32608
Pfizer Investigational Site
Gainesville, Florida, United States, 32610
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Los Angeles, Florida, United States, 90095
Pfizer Investigational Site
Los Angles, Florida, United States, 90095-7349
Pfizer Investigational Site
Miami, Florida, United States, 33136
Pfizer Investigational Site
Miami Beach, Florida, United States, 33140
Pfizer Investigational Site
Orlando, Florida, United States, 32806
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33028
Pfizer Investigational Site
Plantation, Florida, United States, 33324
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30318
Pfizer Investigational Site
Austell, Georgia, United States, 30106
Pfizer Investigational Site
Carrollton, Georgia, United States, 30117
Pfizer Investigational Site
Cartersville, Georgia, United States, 30121
Pfizer Investigational Site
Douglasville, Georgia, United States, 30134
Pfizer Investigational Site
Fayetteville, Georgia, United States, 30214
Pfizer Investigational Site
Marietta, Georgia, United States, 30060
United States, Illinois
Pfizer Investigational Site
Aurora, Illinois, United States, 60504
Pfizer Investigational Site
Chicago, Illinois, United States, 60612
Pfizer Investigational Site
Yorkville, Illinois, United States, 60560
Pfizer Investigational Site
Zion, Illinois, United States, 60099
United States, Kansas
Pfizer Investigational Site
OVerland Park, Kansas, United States, 66210
United States, Maine
Pfizer Investigational Site
Brunswick, Maine, United States, 04011
Pfizer Investigational Site
Sanford, Maine, United States, 04073
Pfizer Investigational Site
Scarborough, Maine, United States, 04074
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21231
Pfizer Investigational Site
Lutherville, Maryland, United States, 21093
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
Pfizer Investigational Site
Grand Rapids, Michigan, United States, 49503
Pfizer Investigational Site
Holland, Michigan, United States, 49424
United States, Minnesota
Pfizer Investigational Site
Edina, Minnesota, United States, 55435
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Pfizer Investigational Site
Ballwin, Missouri, United States, 63011
Pfizer Investigational Site
Kansas City, Missouri, United States, 64131
Pfizer Investigational Site
Kansas City, Missouri, United States, 64154
Pfizer Investigational Site
Kansas City, Missouri, United States, 64111
Pfizer Investigational Site
St Louis, Missouri, United States, 63110
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
Pfizer Investigational Site
St. Louis, Missouri, United States, 63109
Pfizer Investigational Site
St. Louis, Missouri, United States, 63129
United States, Nevada
Pfizer Investigational Site
Henderson, Nevada, United States, 89074
Pfizer Investigational Site
Henderson, Nevada, United States, 89052
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89128
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89148
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89169
United States, New Jersey
Pfizer Investigational Site
New Brunswick, New Jersey, United States, 08901
Pfizer Investigational Site
New Brunswick, New Jersey, United States, 08903
United States, New York
Pfizer Investigational Site
Brewster, New York, United States, 10509
Pfizer Investigational Site
Lake Success, New York, United States, 11042
Pfizer Investigational Site
Mount Kisco, New York, United States, 10549
United States, North Carolina
Pfizer Investigational Site
Asheville, North Carolina, United States, 28806
United States, Ohio
Pfizer Investigational Site
Toledo, Ohio, United States, 43614
Pfizer Investigational Site
Toledo, Ohio, United States, 43617
Pfizer Investigational Site
Toledo, Ohio, United States, 43623
United States, Oregon
Pfizer Investigational Site
Coos Bay, Oregon, United States, 97420
United States, Pennsylvania
Pfizer Investigational Site
Monroeville, Pennsylvania, United States, 15146
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15232
Pfizer Investigational Site
Sayre, Pennsylvania, United States, 18840
United States, Tennessee
Pfizer Investigational Site
Germantown, Tennessee, United States, 38138
United States, Texas
Pfizer Investigational Site
Arlington, Texas, United States, 76104
Pfizer Investigational Site
Burleson, Texas, United States, 76028
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Fort Worth, Texas, United States, 76177
Pfizer Investigational Site
Fort Worth, Texas, United States, 76104
Pfizer Investigational Site
Houston, Texas, United States, 77030
Pfizer Investigational Site
Longview, Texas, United States, 75601
Pfizer Investigational Site
McAllen, Texas, United States, 78503
Pfizer Investigational Site
San Antonio, Texas, United States, 78212
Pfizer Investigational Site
San Antonio, Texas, United States, 78258
Pfizer Investigational Site
San Antonio, Texas, United States, 78217
Pfizer Investigational Site
Tyler, Texas, United States, 75702
Pfizer Investigational Site
Weatherford, Texas, United States, 76086
Pfizer Investigational Site
Weslaco, Texas, United States, 78596
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Pfizer Investigational Site
Arlington, Virginia, United States, 22205
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22908
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22903
Pfizer Investigational Site
Fairfax, Virginia, United States, 22031
Pfizer Investigational Site
Leesburg, Virginia, United States, 20176
Pfizer Investigational Site
Newport News, Virginia, United States, 23606
Pfizer Investigational Site
Norfolk, Virginia, United States, 23502
Pfizer Investigational Site
Reston, Virginia, United States, 20190
Pfizer Investigational Site
Virginia Beach, Virginia, United States, 23456
Pfizer Investigational Site
Winchester, Virginia, United States, 22601
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98104
Pfizer Investigational Site
Seattle, Washington, United States, 98122
United States, Wisconsin
Pfizer Investigational Site
Mequon, Wisconsin, United States, 53097
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53211
Australia, New South Wales
Pfizer Investigational Site
Newcastle, New South Wales, Australia, 2298
Australia, Queensland
Pfizer Investigational Site
Nambour, Queensland, Australia, 4560
Australia, South Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Pfizer Investigational Site
Footscray, Victoria, Australia, 3011
Pfizer Investigational Site
Frankston, Victoria, Australia, 3199
Pfizer Investigational Site
Geelong, Victoria, Australia, 3220
Australia, Western Australia
Pfizer Investigational Site
Perth, Western Australia, Australia, 6000
Australia
Pfizer Investigational Site
Bankstown, Australia, 2200
Pfizer Investigational Site
Brighton, Australia, 3186
Pfizer Investigational Site
East Bentleigh, Australia, 3165
Pfizer Investigational Site
Malvern, Australia, 3144
Pfizer Investigational Site
Southport, Australia, 4215
Pfizer Investigational Site
Victoria, Australia, 8006
Belgium
Pfizer Investigational Site
Edegem, Antwerpen, Belgium, 2650
Pfizer Investigational Site
Ottignies, Brabant Wallon, Belgium, 1340
Pfizer Investigational Site
Charleroi, Hainaut, Belgium, 6000
Pfizer Investigational Site
Haine St. Paul, Hainaut, Belgium, 7100
Pfizer Investigational Site
Tournai, Hainaut, Belgium, 7500
Pfizer Investigational Site
Kingston, ON, Belgium, K7L 5P9
Pfizer Investigational Site
Roselare, West-Vlaanderen, Belgium, 8800
Pfizer Investigational Site
Brussels, Belgium, 1020
Pfizer Investigational Site
Bruxelles, Belgium, 1000
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Libramont, Belgium, 6800
Pfizer Investigational Site
Liège, Belgium, 4000
Pfizer Investigational Site
Namur, Belgium, 5000
Pfizer Investigational Site
Sint-Niklaas, Belgium, 9100
Pfizer Investigational Site
Wilrijk, Belgium, 2610
Canada, British Columbia
Pfizer Investigational Site
Kelowna, British Columbia, Canada, V1Y 5L3
Pfizer Investigational Site
Surrey, British Columbia, Canada, V3V 1Z2
Canada, Ontario
Pfizer Investigational Site
Barrie, Ontario, Canada, L4M 6M2
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 5P9
Pfizer Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1h 8L6
Pfizer Investigational Site
St. Catharines, Ontario, Canada, L2S 0A9
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Pfizer Investigational Site
Toronto, Ontario, Canada, M4C 3E7
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1E2
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1M5
Pfizer Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Pfizer Investigational Site
Montreal, Quebec, Canada, H2W 1S6
Germany
Pfizer Investigational Site
Kiel, SH, Germany, D-24105
Pfizer Investigational Site
Berlin, Germany, 10967
Pfizer Investigational Site
Kiel, Germany, 24103
Pfizer Investigational Site
Kiel, Germany, 24105
Pfizer Investigational Site
Köln, Germany, 50931
Pfizer Investigational Site
Leipzig, Germany, 04103
Pfizer Investigational Site
München, Germany, 80337
Ireland
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland, Dublin 8
Pfizer Investigational Site
Dublin, Ireland, Dublin 9
Pfizer Investigational Site
Sligo, Ireland
Italy
Pfizer Investigational Site
Bagno a Ripoli (FI), Firenze, Italy, 50012
Pfizer Investigational Site
Legnago, Verona, Italy, 37045
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Catania, Italy, 95123
Pfizer Investigational Site
Meldola (FC), Italy, 47014
Pfizer Investigational Site
Milano, Italy, 20141
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Milano, Italy, 20133
Pfizer Investigational Site
Modena, Italy, 41100
Pfizer Investigational Site
Napoli, Italy, Via Mariano Semmola
Pfizer Investigational Site
Palermo, Italy, 90127
Pfizer Investigational Site
Roma, Italy, 00189
Pfizer Investigational Site
Roma, Italy, 00144
Pfizer Investigational Site
Roma, Italy, 00168
Pfizer Investigational Site
Roma, Italy, 00161
Pfizer Investigational Site
Terni, Italy, 05100
Japan
Pfizer Investigational Site
Kashiwa, Chiba, Japan
Pfizer Investigational Site
Matsuyama-city, Ehime, Japan
Pfizer Investigational Site
Kita-adachi-gun, Saitama, Japan
Pfizer Investigational Site
Aichi, Japan
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Fukuoka, Japan
Pfizer Investigational Site
Kagoshima, Japan
Pfizer Investigational Site
Osaka, Japan
Korea, Republic of
Pfizer Investigational Site
Seongnam, Gyunggido, Korea, Republic of, 463-707
Pfizer Investigational Site
Seoul, Republic of Korea, Korea, Republic of, 110-744
Pfizer Investigational Site
Gangnam-gu, Seoul, Korea, Republic of, 135-710
Pfizer Investigational Site
Goyang, Korea, Republic of, 410-769
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Netherlands
Pfizer Investigational Site
Maastricht, Limburg, Netherlands, 6229 HX
Pfizer Investigational Site
Leiden, Zuid-Holland, Netherlands, 2333 ZA
Pfizer Investigational Site
Den Haag, Netherlands, 2545 CH
Pfizer Investigational Site
Rotterdam, Netherlands, 3083 AN
Pfizer Investigational Site
Sittard-Geleen, Netherlands, 6162 BG
Pfizer Investigational Site
Tilburg, Netherlands, 5042AD
Portugal
Pfizer Investigational Site
Lisboa, Portugal, 1400-038
Pfizer Investigational Site
Lisboa, Portugal, 1749-004
Romania
Pfizer Investigational Site
Brasov, Romania, 500091
Pfizer Investigational Site
Bucuresti, Romania, 011464
Pfizer Investigational Site
Ploiesti, Romania, 100337
Pfizer Investigational Site
Sibiu, Romania, 550245
Pfizer Investigational Site
Suceava, Romania, 720237
Pfizer Investigational Site
Tg Mures, Romania, 0540142
Russian Federation
Pfizer Investigational Site
Belgorod, Belgorodskaya oblast', Russian Federation, 308010
Pfizer Investigational Site
Ufa, Republic of Bashkortostan, Russian Federation, 450054
Pfizer Investigational Site
Saint Petersburg, Sankt-Peterburg, Russian Federation, 197022
Pfizer Investigational Site
Pyatigorsk, Stavropol Territory,, Russian Federation, 357502
Pfizer Investigational Site
Chelyabinsk, Russian Federation, 454087
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
Saint Petersburg, Russian Federation, 198255
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 194044
Pfizer Investigational Site
Ufa, Russian Federation, 450054
Pfizer Investigational Site
Velikiy Novgorod, Russian Federation, 173016
Pfizer Investigational Site
village Kuzmolovsky, Russian Federation, 188663
Taiwan
Pfizer Investigational Site
Taiman, Taiwan, 705
Pfizer Investigational Site
Taipei, Taiwan, 100
Turkey
Pfizer Investigational Site
Ankara, Turkey, 06100
Pfizer Investigational Site
Besevler / Ankara, Turkey, 06500
Pfizer Investigational Site
Bornova/Izmir, Turkey, 35100
Pfizer Investigational Site
Sihhiye/Ankara, Turkey, 06100
Ukraine
Pfizer Investigational Site
Poltavs'ka Oblast', Poltava, Ukraine, 36011
Pfizer Investigational Site
Vinnytsia, Vinnyts'ka Oblast', Ukraine, 21029
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49102
Pfizer Investigational Site
m. Chernivtsi, Ukraine, 58013
Pfizer Investigational Site
m. Dnipropetrovsk, Ukraine, 49102
Pfizer Investigational Site
m. Kharkiv, Ukraine, 61070
Pfizer Investigational Site
m. Lviv, Ukraine, 79031
Pfizer Investigational Site
m. Odesa, Ukraine, 65025
Pfizer Investigational Site
m. Poltava, Ukraine, 36011
Pfizer Investigational Site
m. Uzhhorod, Ukraine, 88014
Pfizer Investigational Site
m. Vinnytsia, Ukraine, 21029
Pfizer Investigational Site
Odessa, Ukraine, 65025
Pfizer Investigational Site
Uzhgorod, Ukraine, 88000
United Kingdom
Pfizer Investigational Site
Whitchurch, Cardiff, United Kingdom, CF14 2TL
Pfizer Investigational Site
London, United Kingdom, SW3 6JJ
Pfizer Investigational Site
Portsmouth, United Kingdom, PO6 3LY
Pfizer Investigational Site
Sheffield, United Kingdom, S10 2SJ
Sponsors and Collaborators
Pfizer
AstraZeneca
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01942135     History of Changes
Other Study ID Numbers: A5481023
Study First Received: September 10, 2013
Last Updated: September 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Palbociclib (PD-0332991)
Fulvestrant
Goserelin
Hormone receptor-+
HER2-negative
Prior Endocrine treatment
any menopausal status
PALOMA-3

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Estradiol
Fulvestrant
Hormones
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Antagonists
Estrogen Receptor Modulators
Estrogens
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014